Keyphrases
Phase II Study
100%
Eastern Cooperative Oncology Group
100%
Bronchioloalveolar Carcinoma
100%
Cetuximab
100%
Response Rate
50%
EGFR mutation
50%
KRAS mutation
50%
Patient Characteristics
16%
Advanced Stage
16%
Anticancer Activity
16%
Progression-free Survival
16%
Epidermal Growth Factor Receptor Inhibitors
16%
Growth Factor Receptor Tyrosine Kinase
16%
Chemotherapy Regimen
16%
Adenocarcinoma
16%
Smoking Status
16%
Partial Response
16%
Median Survival
16%
Low Response
16%
Stable Disease
16%
Toxicity Grades
16%
2-cycles
16%
Inhibitor Therapy
16%
Patients Included
16%
Intravenous Infusion
16%
Pyrosequencing
16%
Prior Chemotherapy
16%
Central Pathology Review
16%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
16%
Never-smokers
16%
Eligibility Requirements
16%
Skin Rash
16%
Loading Dose
16%
Initial Loading
16%
Medicine and Dentistry
Oncology
100%
Cetuximab
100%
Lung Alveolus Cell Carcinoma
100%
Epidermal Growth Factor Receptor
66%
Smoking
16%
Adenocarcinoma
16%
Antineoplastic Activity
16%
Pyrosequencing
16%
Exanthem
16%
Patient History of Chemotherapy
16%
Intravenous Drug Administration
16%
Progression Free Survival
16%
Epidermal Growth Factor Receptor Kinase Inhibitor
16%
Loading Drug Dose
16%
Chemotherapy
16%
Diseases
16%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Alveolus Cell Carcinoma
100%
Cetuximab
100%
Epidermal Growth Factor Receptor
66%
Chemotherapy
16%
Adenocarcinoma
16%
Progression Free Survival
16%
Rash
16%
Epidermal Growth Factor Receptor Kinase Inhibitor
16%
Patient History of Chemotherapy
16%
Diseases
16%